Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products.
Since 2012, Merck has been implementing “Fit for 2018” – a transformation program aiming to drive the growth of the company globally. How has this affected the Biopharma operations in Indonesia?
"The fit for 2018 goal entails a huge sense of collaboration in order to come up with the best possible structure for us in the country but also globally."
